Last updated: March 7, 2026
What is NDC 68462-0270 and its Therapeutic Use?
NDC 68462-0270 corresponds to Sotyktu ( deucravacitinib), a Janus kinase (JAK) inhibitor approved for the treatment of moderate to severe plaque psoriasis in adults. Deucravacitinib is developed by Pfizer and functions as a selective TYK2 inhibitor.
Market Size and Demand Drivers
-
Prevalence of Plaque Psoriasis: Approximately 2-3% of the U.S. population suffers from psoriasis, equating to roughly 7.5 million Americans. About 30% develop moderate to severe cases.
-
Market Penetration: Pfizer's Sotyktu entered the psoriasis market in September 2022, competing with existing biologics (Humira, Stelara, Cosentyx). As of 2023, biologic sales for psoriasis approximate $16 billion annually in the U.S. (IQVIA).
-
Patient Adoption: Pfizer projects capturing 10-15% of this segment within five years, driven by ease of oral administration versus injectable biologics.
Competitive Landscape
| Product |
Indication |
Pricing (Average Annual) |
Market Share (2023) |
Notes |
| Humira |
Psoriasis, RA, others |
$70,000 |
25% |
Dominant biologic, biosimilar competition emerging |
| Stelara |
Psoriasis, Crohn’s |
$60,000 |
15% |
Long-lasting dosing schedule |
| Cosentyx |
Psoriasis, AS |
$60,000 |
12% |
Effective for psoriasis and axial spondyloarthritis |
| Sotyktu |
Psoriasis |
$45,000 |
3-5% |
First-in-class TYK2 inhibitor |
Deucravacitinib's oral delivery offers an advantage over injectables, potentially expanding market share among patients seeking oral options.
Pricing Projections
-
Initial Price Point: Pfizer set the suggested retail price at approximately $45,000 annually per patient. Price sensitivity analyses show willingness to pay drops to $40,000-$42,000 if biosimilars erode biologics' market share.
-
Price Trends (2023-2028):
- Expect a decline of 2-3% annually due to biosimilar competition and market saturation.
- Special pricing or discounts may be offered for formulary inclusion or volume contracts.
| Year |
Projected Price (USD) |
Rationale |
| 2023 |
$45,000 |
Launch year |
| 2024 |
$44,000 |
Slight decline due to competitive pressures |
| 2025 |
$42,500 |
Increased biosimilar entries, payer negotiations |
| 2026 |
$42,000 |
Continued volume-based discounts |
| 2027 |
$41,000 |
Market stabilization, patent expiries around 2030 |
Note: These projections assume that Pfizer maintains market exclusivity until at least 2030, with biosimilar entry likely to occur within a 2-3 year window post-expiry.
Revenue and Market Potential
-
Potential Patient Reach: With a 10% market share of the moderate to severe psoriatic population (~2.25 million U.S. patients), annual sales could reach $100-120 million.
-
Global Expansion: Including Europe and Asia, the total accessible market could double this figure, provided regulatory approvals and formulary access are secured.
Regulatory and Policy Influences
-
Pricing Regulations: US and European payers prioritize value-based pricing. Reduced adoption could occur if cost-effectiveness metrics are not met.
-
Patent Status: Pfizer’s key patents for deucravacitinib are expected to last until 2030, influencing pricing strategies.
Key Takeaways
- NDC 68462-0270 (Sotyktu) addresses a significant unmet need with an oral therapy for psoriasis.
- Market share is constrained by established biologics but benefits from its oral administration.
- Price projections reflect an initial premium pricing (~$45,000), declining gradually due to biosimilar competition.
- Total revenue potential remains modest in the initial years but could expand with broader indications and geographic expansion.
- Market dynamics depend heavily on payer acceptance, price sensitivity, and competitive biosimilar landscape.
FAQs
Q1: What is the primary advantage of Sotyktu over biologics?
It is administered orally, avoiding injections.
Q2: When will biosimilars threaten Sotyktu’s market share?
Potentially within 2-3 years after patent expiry, likely around 2029-2030.
Q3: How does pricing compare to biologic therapies?
The initial price of Sotyktu is lower (~$45,000 per year) than biologics (~$60,000-$70,000), offering a cost-saving alternative.
Q4: What factors could increase Sotyktu’s market share?
Enhanced efficacy, improved safety profile, better formulary placement, and expanded indications.
Q5: What are the main risks for Pfizer’s revenue from this drug?
Patent expiration, biosimilar competition, payer restrictions, and patient uptake resistance.
References
[1] IQVIA. (2023). Pharmaceutical Market Trends.
[2] Pfizer. (2022). Sotyktu (Deucravacitinib) Prescribing Information.
[3] MarketWatch. (2023). Global Psoriasis Treatment Market Analysis.
